Literature DB >> 25547118

Personalized one-two punches for lung cancer.

Hannah A Scarborough1, Paul A Bunn2, James DeGregori3.   

Abstract

Discovery of individualized therapies to address resistance to tyrosine kinase inhibitors (TKIs) has been hampered by the inability to test drug combinations on patient samples before and after TKI resistance. A recent study published in Science by Crystal et al. describes a methodology for pharmacological screening using a panel of 76 targeted agents and cell lines made directly from patient biopsies.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25547118      PMCID： PMC4349242          DOI： 10.1038/cr.2014.168

Source DB:  PubMed          Journal:  Cell Res        ISSN： 1001-0602            Impact factor:   25.617


  10 in total

1.  Patient-derived models of acquired resistance can identify effective drug combinations for cancer.

Authors:  Adam S Crystal; Alice T Shaw; Lecia V Sequist; Luc Friboulet; Matthew J Niederst; Elizabeth L Lockerman; Rosa L Frias; Justin F Gainor; Arnaud Amzallag; Patricia Greninger; Dana Lee; Anuj Kalsy; Maria Gomez-Caraballo; Leila Elamine; Emily Howe; Wooyoung Hur; Eugene Lifshits; Hayley E Robinson; Ryohei Katayama; Anthony C Faber; Mark M Awad; Sridhar Ramaswamy; Mari Mino-Kenudson; A John Iafrate; Cyril H Benes; Jeffrey A Engelman
Journal:  Science       Date:  2014-11-13       Impact factor: 47.728

2.  Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.

Authors:  Ryohei Katayama; Alice T Shaw; Tahsin M Khan; Mari Mino-Kenudson; Benjamin J Solomon; Balazs Halmos; Nicholas A Jessop; John C Wain; Alan Tien Yeo; Cyril Benes; Lisa Drew; Jamal Carlos Saeh; Katherine Crosby; Lecia V Sequist; A John Iafrate; Jeffrey A Engelman
Journal:  Sci Transl Med       Date:  2012-01-25       Impact factor: 17.956

Review 3.  The quest to overcome resistance to EGFR-targeted therapies in cancer.

Authors:  Curtis R Chong; Pasi A Jänne
Journal:  Nat Med       Date:  2013-11-07       Impact factor: 53.440

4.  ROCK inhibitor and feeder cells induce the conditional reprogramming of epithelial cells.

Authors:  Xuefeng Liu; Virginie Ory; Sandra Chapman; Hang Yuan; Chris Albanese; Bhaskar Kallakury; Olga A Timofeeva; Caitlin Nealon; Aleksandra Dakic; Vera Simic; Bassem R Haddad; Johng S Rhim; Anatoly Dritschilo; Anna Riegel; Alison McBride; Richard Schlegel
Journal:  Am J Pathol       Date:  2011-12-18       Impact factor: 4.307

5.  Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.

Authors:  Robert C Doebele; Amanda B Pilling; Dara L Aisner; Tatiana G Kutateladze; Anh T Le; Andrew J Weickhardt; Kimi L Kondo; Derek J Linderman; Lynn E Heasley; Wilbur A Franklin; Marileila Varella-Garcia; D Ross Camidge
Journal:  Clin Cancer Res       Date:  2012-01-10       Impact factor: 12.531

6.  Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors.

Authors:  Lecia V Sequist; Belinda A Waltman; Dora Dias-Santagata; Subba Digumarthy; Alexa B Turke; Panos Fidias; Kristin Bergethon; Alice T Shaw; Scott Gettinger; Arjola K Cosper; Sara Akhavanfard; Rebecca S Heist; Jennifer Temel; James G Christensen; John C Wain; Thomas J Lynch; Kathy Vernovsky; Eugene J Mark; Michael Lanuti; A John Iafrate; Mari Mino-Kenudson; Jeffrey A Engelman
Journal:  Sci Transl Med       Date:  2011-03-23       Impact factor: 17.956

Review 7.  Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.

Authors:  Kim-Son H Nguyen; Susumu Kobayashi; Daniel B Costa
Journal:  Clin Lung Cancer       Date:  2009-07       Impact factor: 4.785

8.  Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer.

Authors:  Lucia Regales; Yixuan Gong; Ronglai Shen; Elisa de Stanchina; Igor Vivanco; Aviva Goel; Jason A Koutcher; Maria Spassova; Ouathek Ouerfelli; Ingo K Mellinghoff; Maureen F Zakowski; Katerina A Politi; William Pao
Journal:  J Clin Invest       Date:  2009-09-14       Impact factor: 14.808

Review 9.  Bypass mechanisms of resistance to receptor tyrosine kinase inhibition in lung cancer.

Authors:  Matthew J Niederst; Jeffrey A Engelman
Journal:  Sci Signal       Date:  2013-09-24       Impact factor: 8.192

10.  Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.

Authors:  Jenifer L Marks; Yixuan Gong; Dhananjay Chitale; Ben Golas; Michael D McLellan; Yumi Kasai; Li Ding; Elaine R Mardis; Richard K Wilson; David Solit; Ross Levine; Kathrin Michel; Roman K Thomas; Valerie W Rusch; Marc Ladanyi; William Pao
Journal:  Cancer Res       Date:  2008-07-15       Impact factor: 12.701
  10 in total
  2 in total

1.  Urea Cycle Sustains Cellular Energetics upon EGFR Inhibition in EGFR-Mutant NSCLC.

Authors:  Catherine Pham-Danis; Sarah Gehrke; Etienne Danis; Andrii I Rozhok; Michael W Daniels; Dexiang Gao; Christina Collins; José T Di Paola; Angelo D'Alessandro; James DeGregori
Journal:  Mol Cancer Res       Date:  2019-02-26       Impact factor: 5.852

Review 2.  Role and targeting of anaplastic lymphoma kinase in cancer.

Authors:  Carminia Maria Della Corte; Giuseppe Viscardi; Raimondo Di Liello; Morena Fasano; Erika Martinelli; Teresa Troiani; Fortunato Ciardiello; Floriana Morgillo
Journal:  Mol Cancer       Date:  2018-02-19       Impact factor: 27.401
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.